On the upside
Shares of Sarepta Therapeutics (Nasdaq: SRPT) continued climbing after a news report yesterday highlighted positive results in a small, mid-stage trial of the company's Duchenne Muscular Dystrophy treatment Eteplirsen.
Dahlman Rose upgraded Thompson Creek Metals (NYSE: TC) to a Buy rating.
On the downside
An appeals court remanded Akamai's (Nasdaq: AKAM) patent infringement suit against Limelight Networks (Nasdaq: LLNW). Shares of Zynga (Nasdaq: ZNGA) fell after analysts slashed their price targets for Facebook (Nasdaq: FB).
Shares of Digital Domain Media (NYSE: DDMG) continued falling.
In the broad market, advancing outpaced decliners by a margin of 2 to 1 on the NYSE and by nearly 5 to 3 on Nasdaq. The Russell 2000 which tracks small cap stocks added a point to 810.